

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: EISENBACH-SCHWARTZ et al

Application No.: 09/218,277

Filed: December 22, 1998

For: T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND THEIR USES

Art Unit: 1647

Examiner: S. Turner

Washington, D.C.

Atty.'s Docket: EIS-SCHWARTS=1A

Date: May 11, 2001

BY HAND-CARRYING

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is an ☐ Amendment ☒ Supplemental Response and Michal Eisenbach-Schwartz Declaration
in the above-identified application.

☒ Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

☒ No additional fee is required.

☐ The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	* 17	MINUS	** 20	0
INDEP.	* 1	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

ADDITIONAL FEE TOTAL

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 40	\$
+ 135	\$
ADDITIONAL FEE TOTAL	
	\$

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 80	\$
+ 270	\$
TOTAL	
	\$

OR

OR

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- ☐ First - \$ 55.00
- ☐ Second - \$ 195.00
- ☐ Third - \$ 445.00
- ☐ Fourth - \$ 695.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

- ☐ First - \$ 110.00
- ☐ Second - \$ 390.00
- ☐ Third - \$ 890.00
- ☐ Fourth - \$ 1390.00

Month After Time Period Set

☐ Less fees (\$) already paid for month(s) extension of time on

☐ Please charge my Deposit Account No. 02-4035 in the amount of \$

☐ Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$


☐ A check in the amount of \$ is attached (check no.).

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

Facsimile: (202) 737-3528
Telephone: (202) 628-5197

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By 
Roger L. Browdy
Registration No. 25,618

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: EIS-SCHWARTZ=1A

In re Application of:)	Art Unit: 1647
)	
EISENBACH-SCHWARTZ et al)	Examiner: S. Turner
)	
Appln. No.: 09/218,277)	Washington, D.C.
)	
Filed: December 22, 1998)	May 11, 2001
)	
For: T-CELLS, NERVOUS SYSTEM-)	
SPECIFIC ANTIGENS AND)	
THEIR USES)	BY HAND-CARRYING

SUPPLEMENTAL RESPONSE

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

Supplementing applicants' amendment of March 5, 2001, attached hereto is a declaration executed by Michal Eisenbach-Schwartz, confirming the truth and accuracy of the experimentation detailed in the papers: Hauben et al, "Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion", J Neurosci 20(17):6421-6430 (2000); and Hauben et al, "Autoimmune T cells as potential neuroprotective therapy for spinal cord injury", Lancet 355(9200):286-287 (2000).

Please consider this Supplemental Response and the attached Declaration in conjunction with applicants' amendment of March 5, 2001.


In re of Appln. No. 09/218,277

Reconsideration and allowance are earnestly
solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By


Roger L. Browdy
Registration No. 25,618

RLB:rd
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
F:\,Y\YEDA\Eis-Schwartz1A\PTO\SupResponse.doc